High risk of hepatitis B virus reactivation among patients treated with direct-acting antivirals and coinfected with HCV and HIV

We recently read the article by Corma-G ómez A. et al. on which the authors described a higher probability of relapses with sofosbuvir/ledipasvir 8 weeks compared with 12 weeks of HCV (hepatitis C virus) among HIV (human immunodeficiency virus)/HCV coinfected patients.1 In this regard, coinfections of HIV/ HCV also with hepatitis B virus (HBV) is associated with high mortality and comorbidity too. The persistence of HBV DNA within the core cell in the absence of HBsAg and even after clearance of the infection has been described previously in immunosuppressed patients, where HBV screening and prophylaxis is recommended.
Source: Journal of Infection - Category: Infectious Diseases Authors: Tags: Letter to the Editor Source Type: research